Developing new mRNA vaccines to improve melanoma treatment
Multivalent Small Circular mRNA Vaccines for Melanoma Combination Immunotherapy
This study is testing a new type of small vaccine designed to boost the effectiveness of current melanoma treatments, helping your immune system fight the cancer better and longer.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Michigan at Ann Arbor NIH-funded |
| Lab location | 1 site (Ann Arbor, United States) |
| Project ID | NIH-10990224 on NIH RePORTER |
What this research studies
This research focuses on creating innovative small circular mRNA vaccines aimed at enhancing the effectiveness of existing melanoma treatments, particularly immune checkpoint blockade therapy. By addressing the limitations of conventional vaccines, such as stability and immune response, the study aims to develop a more effective immunotherapy option. The approach involves using highly stable, modification-free multivalent small circular mRNA that can efficiently stimulate the immune system to target melanoma cells. Patients may benefit from a more robust and lasting immune response against their cancer.
Who could benefit from this research
Good fit: Ideal candidates for this research are melanoma patients who have not responded to current immune checkpoint blockade therapies.
Not a fit: Patients with early-stage melanoma or those who have not yet undergone any form of immunotherapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective melanoma treatments that improve patient outcomes and survival rates.
How similar studies have performed: Previous research has shown promise in using mRNA vaccines for cancer treatment, indicating potential success for this novel approach.
Where this research is happening
Ann Arbor, United States
- University of Michigan at Ann Arbor — Ann Arbor, United States (Active)
Researchers
- Principal investigator: Zhu, Guizhi — University of Michigan at Ann Arbor
- Study coordinator: Zhu, Guizhi
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.